Diabetes Care Flashcards
1
Q
insulin
A
- release from beta cells of pancreas
- basal rate - small pulses
- bolus rate - larger amounts to cove meals
2
Q
glucose metabolism and liver
A
- low BG sensed by alpha cells
- glucagon released
- liver converts glycogen to glucose and release in bloodstream
- gluconeogenesis and release
3
Q
gluconeogenesis
A
formation of glucose
4
Q
glycogenolysis
A
- transformation of glycogen to glucose
5
Q
type 1 diabetes
A
- 10%
- destruction of beat cells
- insulin
6
Q
type 2 diabetes
A
- 85%
- defective beat cells and decreased insulin sensitivity
- lifestyle modifications and PO hypoglycemics
7
Q
signs and symptoms of DM
A
- polyphasic - increased hunger
- polyuria - increased urination
- polydipsia - increased thirst
- recurrent utis/yeast infections
- sore that won’t heal
8
Q
diabetes diagnosis
A
- FPG >7.0mmol/L
- A1C >6.5%
- 2hPG in a 75g OGTT >11.1mmol/L
- random PG >11.1mmol/L
9
Q
honeymoon period
A
- when first started on insulin may need lower doses as beta cells are kickstarted
- 3-12 months
10
Q
short acting/regulat
A
- onset = 30 mins
- peak = 2-3 hr
- duration = 6.5hr
- only regular can be given IV
- Humulin R, NPH
11
Q
rapid acting
A
- onset = 10-15 mins
- peak = 60-90 mins
- duration = 3-5 hrs
- eat right after
- often used with CHO counting
- Humalog (lispro), Aspart (NovoLog), glargine (Apidra)
12
Q
long acting
A
- onset = 90 mins
- peak = no peak as consistently release
- duration = 24hrs
- once daily often HS
- no mixing
- glargine (Lantus), detemir (Levemir), degludec (tresiba), humulin N
13
Q
pharmacological treatment of type 2
A
- start with diet/exercise trial
- oral hypoglycemics only type 2
- often combo with insulin
- 6 classes
- not given with gestational diabetes or pregnant type 2
14
Q
how many people with type 2 DM eventually require insulin
A
50%
15
Q
metformin (Glucophage)
A
- biguanide
- suppress hepatic glucose production and increase glucose uptake by cells
- no hypoglycaemia risk
- hold for CT dye to let it be excreted by kidneys (48hrs after procedure)
16
Q
insulin secretagogues
A
- increase insulin production by pancreas
- hypoglycemics risk
- can speed pancreas exhaustion
- sulfonylureas and nonsulfonylureas
- *sulfa allergy
17
Q
beta blockers and diabetes
A
- blocks epinephrin resulting in hypoglycemics unawareness
18
Q
incretin agents
A
- acts on hormone in GI D-PP4 inhibitors and GLP1
- stimulates pancreas to secrete more insulin and decrease glucose production by liver
- hypoglycaemia risk
- GI side effects
- injection
19
Q
sodium glucose linked transporter protein inhibitor (SGLT-2)
A
- new class PO med
- decrease glucose reabsorption by kidneys
- no hypoglycaemia risk
- risk for uti/yeast infection
- cardiac benefits
20
Q
insulin sensitizers
A
- thiazolidinediones (TZD)
- increases insulin sensitivity at cell receptors = decreased insulin resistance
- no hypoglycaemia risk
- increased MI risk, contraindicated in CHF
- 8-12 wk peak
21
Q
alpha glucosidase inhibitor
A
- decreases GI carb absorption
- prandase
22
Q
chronic complications
A
- microvascular and macrovascular
- optimal glucose control = less complications but more hypoglycemics events
23
Q
macrovascular complications
A
- CAD
- CVA
- PVD
- changes to coronary, cerebral, and peripheral vessels
- atherosclerosis increased and earlier
- abnormal clotting factors